In addition, to investigate whether high MYC levels might be useful for prospectively predicting sensitivity to combined KRAS G12C/eIF4A inhibitors, human KRAS G12C–mutant NSCLC explants expressing either high levels of MYC (DFCI-730, DFCI-456, MGH-9029-1B) or low levels of MYC (MGH-1112-1, MGH-1196-2) were used to generate patient-derived organotypic tumor spheroids (PDOTSs) (33). The gene discussed is KRAS; the disease is neoplasm.